- Satellos Bioscience (MSCL) reports preclinical progress with the drug SAT-3153
- Satellos is a biotechnology company that develops life-changing medicines to treat degenerative muscle conditions
- SAT-3153 has been designated by Satellos, and the company is pursuing pre-IND development activities
- Many studies have been conducted to date
- New results bring the drug SAT-3153 one step closer to using it as a treatment
- Satellos Bioscience (MSCL) is trading at C$0.03 at 9:41 am EST
The duo-listed company, Satellos Bioscience (MSCL), has released additional results from preclinical studies for drug candidate SAT-3153.
SAT-3153 has been designated by Satellos as its lead drug candidate, and the company is pursuing pre-IND development activities.
New results for SAT-3153
In January, Satellos indicated that results from preclinical ADME, PK and in vivo studies led to the designation of SAT-3153 as its lead pre-IND drug development candidate for treating Duchenne muscular dystrophy.
“[The drug] has the potential to be safe on critical drug development criteria,” said Frank Gleeson, President and CEO of Satellos.
Additionally, another study showed that in an acute injury model intended to determine if the drug is acting rapidly on the mechanism, Mdx mice treated with SAT-3153 displayed a massive effect on polarity through new progenitor muscle cell formation vs placebo after one week.
Other preclinical studies have shown that the drug does not bind to the hERG channel (a key requirement to rule out possible cardiac toxicity).
“As preliminary, fact-finding studies which were designed to contribute to the profile of SAT-3153 as a DC and establish early efficacy benchmarks to guide further development studies, we are very pleased with these outcomes,” added Gleeson.
Dr. Phil Lambert, Chief Technical Officer with overall responsibility for drug development at Satellos, added that the latest results are positive and bring the company one step closer to using the drug as a treatment.
“We will now focus on the next steps in the process, including establishing the preferred oral dosing paradigm to optimize the drug’s beneficial effects on skeletal muscle, which we believe have the potential to be cumulative and sustainable over time,” commented Dr. Lambert.
Satellos states that a dysfunction in the normal process of stem cell polarity in response to muscle damage represents Duchenne’s previously unrecognized root cause.
The goal of correcting polarity in Duchenne is to restore the body’s ability to regenerate muscle in response to ongoing damage experienced by people living with Duchenne.
Satellos is a biotechnology company that develops life-changing medicines to treat degenerative muscle conditions.
Satellos Bioscience (MSCL) is trading at C$0.03 at 9:41 am EST.
